Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up - Still a Buy?

Key Points

• Chugai Pharmaceutical's shares gapped up from a previous close of $21.15 to an opening of $22.40 before trading at $22.13.
• For the last quarter, the company reported an EPS of $0.20 and revenue of $2.01 billion, with a net margin of 33.08%.
• Chugai Pharmaceutical has a market cap of $72.51 billion and analysts predict an EPS of 0.74 for the current year.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $21.15, but opened at $22.40. Chugai Pharmaceutical shares last traded at $22.13, with a volume of 84,506 shares trading hands.

Chugai Pharmaceutical Price Performance

The company's 50 day moving average is $23.69 and its 200 day moving average is $24.67. The stock has a market cap of $70.49 billion, a price-to-earnings ratio of 27.11 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 EPS for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The firm had revenue of $2.01 billion during the quarter. Sell-side analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.